Your browser doesn't support javascript.
loading
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).
Maruyama, Dai; Iida, Shinsuke; Machida, Ryunosuke; Kusumoto, Shigeru; Fukuhara, Noriko; Yamauchi, Nobuhiko; Miyazaki, Kana; Yoshimitsu, Makoto; Kuroda, Junya; Tsukamoto, Norifumi; Tsujimura, Hideki; Usuki, Kensuke; Yamauchi, Takahiro; Utsumi, Takahiko; Mizuno, Ishikazu; Takamatsu, Yasushi; Nagata, Yasuyuki; Ota, Shuichi; Ohtsuka, Eiichi; Hanamura, Ichiro; Suzuki, Yasuhiro; Yoshida, Shinichiro; Yamasaki, Satoshi; Suehiro, Youko; Kamiyama, Yutaro; Fukuhara, Suguru; Tsukasaki, Kunihiro; Nagai, Hirokazu.
Afiliação
  • Maruyama D; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Iida S; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
  • Machida R; JCOG Data Center, National Cancer Center Hospital, Tokyo, Japan.
  • Kusumoto S; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
  • Fukuhara N; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
  • Yamauchi N; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Miyazaki K; Department of Hematology and Oncology, Mie University School of Medicine, Tsu, Japan.
  • Yoshimitsu M; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
  • Kuroda J; Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Tsukamoto N; Department of Hematology, Gunma University Hospital, Maebashi, Japan.
  • Tsujimura H; Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
  • Usuki K; Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Yamauchi T; Department of Hematology and Oncology, University of Fukui, Fukui, Japan.
  • Utsumi T; Department of Hematology, Shiga General Hospital, Moriyama, Japan.
  • Mizuno I; Department of Hematology, Hyogo Cancer Center, Akashi, Japan.
  • Takamatsu Y; Division of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan.
  • Nagata Y; Department of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Ota S; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Ohtsuka E; Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
  • Hanamura I; Division of Hematology, Aichi Medical University, Nagakute, Japan.
  • Suzuki Y; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Yoshida S; Department of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
  • Yamasaki S; Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
  • Suehiro Y; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Kamiyama Y; Department of Clinical Oncology and Hematology, The Jikei University Hospital, Tokyo, Japan.
  • Fukuhara S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Tsukasaki K; Department of Hematology, International Medical Centre, Saitama Medical University, Saitama, Japan.
  • Nagai H; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Cancer Sci ; 113(9): 3267-3270, 2022 09.
Article em En | MEDLINE | ID: mdl-35909244
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Idioma: En Ano de publicação: 2022 Tipo de documento: Article